SCHEMBL3555307

SCHEMBL3555307

N#Cc1ccc(C2C[N]C2)cn1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHEK1 O14757 4/20 0.33
SLC6A3 Q01959 1/20 0.33
KCNH2 Q12809 1/20 0.33
TAAR1 Q96RJ0 1/20 0.33
KDM1A O60341 2/20 0.33
ELANE P08246 2/20 0.32
EGLN2 Q96KS0 1/20 0.32
FASN P49327 1/20 0.32
ADRB1 P08588 1/20 0.32
HTR1A P08908 1/20 0.32
CYP2C9 P11712 1/20 0.32
HRH3 Q9Y5N1 1/20 0.32
ALOX5AP P20292 1/20 0.30
FEN1 P39748 1/20 0.30
KDM4E B2RXH2 1/20 0.30
GLA P06280 1/20 0.30
HTT P42858 1/20 0.30
KMT2A Q03164 1/20 0.30
SMN1; SMN2 Q16637 1/20 0.30
HIF1A Q16665 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2860558 0.85 KDM4E (0.39) CHEK1SLC6A3KCNH2TAAR1KDM1A
SCHEMBL14045979 0.80 KDM4E (0.50) CHEK1KCNH2FASNHRH3ALOX5AP
SCHEMBL22047801 0.77 CHEK1 (0.40) CHEK1KDM1AFASNALOX5APFEN1
SCHEMBL12049591 0.77 CHEK1 (0.43) CHEK1ELANEEGLN2FASNADRB1
SCHEMBL18721893 0.77 ESR2 (0.44) CHEK1ELANEFASNADRB1HTR1A
SCHEMBL3237238 0.76 ESR2 (0.46) CHEK1SLC6A3KCNH2TAAR1ELANE
Hydrochloric Acid SCHEMBL12489003 0.76 CHEK1 (0.49) CHEK1SLC6A3KCNH2TAAR1
SCHEMBL13470580 0.75 FASN (0.39) CHEK1FASNHRH3
SCHEMBL12686799 0.75 FASN (0.39) CHEK1SLC6A3KCNH2TAAR1FASN
SCHEMBL27722944 0.75 HTR3A (0.47) CHEK1SLC6A3KCNH2TAAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7834015-B2 treatment of cancer, inflammatory diseases, reperfusion injuries, ischaemic conditions, stroke, renal failure, cardiovascular diseases, neurodegenerative diseases, retroviral infections, retinal damage, skin senescence and UV skin damage, and as chemosensitizers or radiosensitizers for cancer treatment INSTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) 2010-11-16 US disclosed
US-20090209523-A1 Pyrrolo[1,2-A] Pyrazin-1(2H)-One and Pyrrolo[1,2-D][1,2,4]Triazin-1(2H)-One Derivatives as Inhibitors of Poly(Adp-Ribose)Polymerase (Parp) ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) 2009-08-20 US disclosed
EP-2032140-A1 PYRROLO[1,2-A]PYRAZIN-1(2H)-ONE AND PYRROLO[1,2-D][1,2,4]TRIAZIN-1(2H)-ONE DERIVATIVES AS INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE(PARP) Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. (IT) 2009-03-11 EP disclosed
WO-2007138355-A1 PYRROLO[1,2-A]PYRAZIN-1(2H)-ONE AND PYRROLO[1,2-D][1,2,4]TRIAZIN-1(2H)-ONE DERIVATIVES AS INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE(PARP) ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) 2007-12-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090209523-A1 Pyrrolo[1,2-A] Pyrazin-1(2H)-One and Pyrrolo[1,2-D][1,2,4]Triazin-1(2H)-One Derivatives as Inhibitors of Poly(Adp-Ribose)Polymerase (Parp) PARP1, PARP2, PARP11 CHEK1 53/4885SLC6A3 4532/4885KCNH2 3777/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.